Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Impact · against what's priced in

The news is neutral for Regeneron as the strong performance of Dupixent and the ongoing erosion of Eylea are already core components of the current valuation. Sanofi remains positive based on high peak revenue targets for Dupixent, though the article provides no new catalysts beyond previous projections.

REGN+0.00

Already priced in

The price assumes

The current revenue mix, where collaboration revenue grows at 21% while product revenue declines 17%, is fully assumed.